By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD#03 – Ron Krauss, M.D.: a deep dive into heart disease
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
At a glance
WHAT IT’S REALLY ABOUT
Ron Krauss and Peter Attia Dissect Atherosclerosis, LDL Particles, Statins, and Niacin
- Krauss describes atherosclerosis as starting in childhood as benign fatty streaks that become dangerous when oxidized, inflammation-triggering lipoproteins weaken the plaque's fibrous cap and a rupture causes a clot.
- The two discuss why LDL particle number (ApoB) can diverge from LDL cholesterol, and Krauss argues that small LDL, remnants, and long circulation time add risk, though he concedes the evidence on particle size independence is not settled.
- Krauss supports LDL causality with genetic evidence, including familial hypercholesterolemia, PCSK9 mutations, and Mendelian randomization from a European consensus paper he co-authored, while cautioning that lowering LDL is not always beneficial.
- On statins, Krauss and Attia cover diabetes risk, differences between statins, myopathy mechanisms, inflammation, and uncertainty over lifelong use and use after age 75, and both say that combining a statin with a PCSK9 inhibitor makes more sense than replacing the statin.
- Krauss explains that the AIM-HIGH and HPS2 niacin trials showed HDL raising is not protective, yet he still uses niacin for patients with small LDL, elevated Lp(a), or moderately elevated triglycerides.
IDEAS WORTH REMEMBERING
5 ideasAtherosclerosis begins early and accumulates with exposure.
Krauss says fatty streaks form in childhood, and Attia notes age is the greatest risk factor because it reflects cumulative exposure, with sudden death as the first presentation for roughly 30 percent of people by Krauss's rough estimate.
The particle, not the cholesterol measurement, is the causal agent.
Each LDL particle carries one ApoB, so ApoB counts particles better than LDL-C, and discordance between the two is common, especially in metabolic syndrome.
Residence time in the blood is a unifying driver of risk.
Krauss argues that particles cleared slowly by LDL receptors, including small LDL and remnants, circulate longer and have more opportunity to damage arteries; he calls remnants perhaps the most pathologic particles.
LDL causality is strongly supported but not absolute for every case.
Genetic evidence such as familial hypercholesterolemia, PCSK9 variants, and Mendelian randomization supports causality, yet Krauss notes some LDL under certain conditions may not be harmful and lowering it may not always help.
Statins carry real but manageable trade-offs.
Krauss cites about a 10 percent average rise in diabetes risk, possibly higher in women, and says statin effects on muscle, mitochondria, and possibly the brain are still being studied, while stressing that benefits generally outweigh risks for people whose risk merits treatment.
WORDS WORTH SAVING
5 quotesStatins are tools, and the most important thing when you have a tool is knowing how to use it and knowing when to use it.
— Peter Attia
Just because lowering LDL cholesterol is not always beneficial doesn't mean that LDL is not pathological.
— Dr. Ron Krauss
It's the particles that are causal, and LDL cholesterol, as we just talked about, does not always mirror the number of LDL particles.
— Dr. Ron Krauss
We are conducting an experiment in the global population, certainly in the U.S., that has never been done before, and that is prescribing statins to millions of people as a lifelong treatment without knowing what the downstream effects are.
— Dr. Ron Krauss
The failure of those trials speaks to the success of statins and the failure of HDL raising.
— Dr. Ron Krauss
High quality AI-generated summary created from speaker-labeled transcript.
